Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...

PSEB Class 10 supplementary exam is scheduled to be held from July 6 to 10, Class 12 compartment exam from July 4 to 6, 2026.

NCERT’s latest textbook changes under NEP 2020—from adding the 1975–77 Emergency to reducing Mughal history, revising Gandhi assassination references, dropping evolution and Gujarat riots content—have ...

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, in a deal that would expand the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

First in a three-part series. This story was produced with support from the Pulitzer Center. In the past four springs, state employees in small planes and a helicopter have combed the skies of ...

CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology ...

Many scientific problems entail labeling data items with one of a given, finite set of classes based on features of the data items. For example, oncologists classify tumors as different known cancer ...

New 2026 research from Finland finds HIF-PHI anemia medications may slow cancer cell growth and block tumor blood vessels ...

Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver ...